These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30076906)

  • 1. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
    Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
    J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
    Leitner L; Walter M; Freund P; Mehnert U; Michels L; Kollias S; Kessler TM
    BMC Urol; 2014 Aug; 14():68. PubMed ID: 25132340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis.
    Elizondo RA; Karmonik C; Boone TB; Khavari R
    BMJ Open; 2017 Feb; 7(2):e013225. PubMed ID: 28159850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Magnetic Resonance Imaging with Concurrent Urodynamic Testing Identifies Brain Structures Involved in Micturition Cycle in Patients with Multiple Sclerosis.
    Khavari R; Karmonik C; Shy M; Fletcher S; Boone T
    J Urol; 2017 Feb; 197(2):438-444. PubMed ID: 27664581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
    Honda M; Yokoyama O; Takahashi R; Matsuda T; Nakayama T; Mogi T
    Int J Urol; 2021 Sep; 28(9):906-912. PubMed ID: 34075630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
    Ferreira RS; D'Ancona CAL; Oelke M; Carneiro MR
    Einstein (Sao Paulo); 2018 Aug; 16(3):eAO4207. PubMed ID: 30088545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA and multiple sclerosis.
    Schurch B; Carda S
    Ann Phys Rehabil Med; 2014 Jul; 57(5):302-314. PubMed ID: 24953702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
    Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.